Summary
Losartan Potassium has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. ClinicalTrials.gov lists 8 registered trials linking Losartan Potassium to Chronic Kidney Disease: 4 have completed; 4 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00140985). The largest enrolment is 600 participants (NCT05271448). Registration activity spans 2000 to 2021. The literature layer holds 4 publications for this pair: 1 Cochrane review and 3 clinical trial publications. Publication years run from 2003 to 2023. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Chronic Kidney Disease ranks 534 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: GFR decline averages 2-5 mL/min/year on standard care (ACE/ARB + blood pressure control); progression to end-stage renal disease (ESRD) in ~20-30% at 10 years for moderate CKD; reversal essentially impossible once structural fibrosis established.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 49.5 (trials 18.5, literature 11.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 4 completed, 4 other |
| Linked publications | 4 (3 clinical trial publications, 1 Cochrane review) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | AGTR1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00140985 | Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213) 2000 | completed | Phase 4 | 97 |
| NCT02232763 | Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria 2014 | completed | Phase 3 | 58 |
| NCT01087749 | Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers 2010 | completed | Phase 1 | 24 |
| NCT00231803 | The Canadian Prevention of Renal and Cardiovascular Endpoints Trial 2005 | completed | Not applicable | 474 |
| NCT00565396 | Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 2004 | status unknown | Not applicable | 400 |
| NCT05271448 | Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography 2021 | status unknown | Not applicable | 600 |
| NCT03603938 | Bedtime Potassium Losartan on CKD With Nocturnal Hypertension Patients With Nondipping Blood Pressure Pattern 2018 | status unknown | Not applicable | 189 |
| NCT04078711 | Chinese Medicine Treat for Hypertensive Renal Injury 2019 | status unknown | PHASE2, PHASE3 | 520 |
Published literature
- Cochrane review [Efficacy, safety, and mechanism of Huangkui Capsules in treating chronic kidney disease: Meta-analysis and integrative bioinformatics]Wang FP, Zhang L, Lyu J et al. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica · 2023 · PMID 37802876
- Clinical trial publication [Effect of Chuanhuang No. 1 recipe on renal function and micro-inflammation in phase 3 chronic kidney disease patients]Gong XZ, Zhou LF, Wang Q et al. · Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine · 2015 · PMID 25881455
- Clinical trial publication Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trialZhang L, Li P, Xing CY et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2014 · PMID 24631042
- Clinical trial publication Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL studyBakris GL, Weir MR, Shanifar S et al. · Archives of internal medicine · 2003 · PMID 12860578
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Losartan Potassium approved for Chronic Kidney Disease?
Losartan Potassium has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Losartan Potassium in clinical trials for Chronic Kidney Disease?
ClinicalTrials.gov lists 8 registered trials linking Losartan Potassium to Chronic Kidney Disease: 4 have completed; 4 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00140985). The largest enrolment is 600 participants (NCT05271448). Registration activity spans 2000 to 2021.
What does the evidence show for Losartan Potassium in Chronic Kidney Disease?
Losartan Potassium has both completed registered trials and synthesis-level publications linked to Chronic Kidney Disease. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.